Inventiva Secures €20.1M in Funding to Advance NASH Treatment
Inventiva Secures €20.1M in Funding to Advance NASH Treatment
inventiva獲得2010萬歐元的資金以推進NASH治療
Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the issuance of royalty certificates (the "Royalty Certificates") subscribed by Samsara BioCapital, BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of approximately €20.1 million (the "Transaction").
Inventiva（納斯達克：IVA）（"Inventiva"或"公司"），一家專注於開發口服小分子療法治療代謝功能障礙脂肪肝（"MASH"），又稱非酒精性脂肪肝（"NASH"）患者以及其他存在重大未滿足醫療需求的疾病的臨床階段生物製藥公司，今天宣佈發行由Samsara BioCapital，BVF Partners，NEA，Sofinnova和Yiheng認購的版稅證書（"Royalty Certificates"），金額爲約€2010萬（"交易"）。
Frederic Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva stated: "Besides extending our cash runway, this agreement demonstrates the commitment from our key shareholders...
Inventiva的董事長，首席執行官兼聯合創始人...
登入免費觀看全文
登入/註冊